Agents that affect the renin-angiotensin system and BB have been recommended as class I recommendations for heart failure for several years [38, 39], but immediate prescription of both MRA, SGLT2 inhibitors, agents that affect the renin-angiotensin system, and BB was not implemented in ESC guidelines until 2021 [1, 2]. Here, REN is linked to heart failure.